Determination of Beta-Defensin Genomic Copy Number in Different Populations: A Comparison of Three Methods

Peder Fode1, Cathrine Jespersgaard2,3, Robert J. Hardwick3, Helen Bogle1, Michael Theisen2, Daniel Dodoo4, Martin Lenicek5,6, Libor Vitek5,6, Ana Vieira7, Joao Freitas7, Paal Skytt Andersen1, Edward J. Hollox3

1 Department for Microbiological Surveillance and Research, Statens Serum Institut, Copenhagen, Denmark, 2 Department of Clinical Biochemistry and Immunology, Statens Serum Institut, Copenhagen, Denmark, 3 Department of Genetics, University of Leicester, Leicester, United Kingdom, 4 Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana, 5 Department of Clinical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 6 4th Department of Internal Medicine, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 7 Department of Gastroenterology, Hospital Garcia de Orta, Almada, Portugal

Abstract

Background: There have been conflicting reports in the literature on association of gene copy number with disease, including CCL3L1 and HIV susceptibility, and β-defensins and Crohn’s disease. Quantification of precise gene copy numbers is important in order to define any association of gene copy number with disease. At present, real-time quantitative PCR (QPCR) is the most commonly used method to determine gene copy number, however the Paralogue Ratio Test (PRT) is being used in more and more laboratories.

Findings: In this study we compare a Pyrosequencing-based Paralogue Ratio Test (PPRT) for determining beta-defensin gene copy number with two currently used methods for gene copy number determination, QPCR and triplex PRT by typing five different cohorts (UK, Danish, Portuguese, Ghanaian and Czech) of DNA from a total of 576 healthy individuals. We found a systematic measurement bias between DNA cohorts revealed by QPCR, but not by the PRT-based methods. Using PRT, copy number ranged from 2 to 9 copies, with a modal copy number of 4 in all populations.

Conclusions: QPCR is very sensitive to quality of the template DNA, generating systematic biases that could produce false-positive or negative disease associations. Both triplex PRT and PPRT do not show this systematic bias, and type copy number within the correct range, although triplex PRT appears to be a more precise and accurate method to type beta-defensin copy number.

Introduction

Characterization of genetic variants is fundamental in understanding human heterogeneity and susceptibility to disease. Regions where humans differ in diploid DNA dosage are known as copy number variations (CNVs) and are an important component of genetic variation. CNVs are believed to encompass more nucleotide content than single nucleotide polymorphisms (SNPs) [1] and between 12% and 18% [2,3] of the euchromatic human genome is suggested to be copy number variable [4]. The use of array-comparative genomic hybridisation (array-CGH) and next-generation sequencing techniques will probably reveal an even greater proportion of structural variation among individuals and populations [5,6]. CNVs can alone or in combination with SNPs correlate with certain diseases, or are associated with increased susceptibility to diseases [7–9] including psoriasis [10–12], autism [13], cancer [14], schizophrenia [15–17], systemic lupus erythematosus [18–20], Alzheimer’s disease [21], Charcot-Marie-Tooth disease [22,23], Parkinson’s disease [24] and autoimmunity [25].

One region showing extensive CNV is found in the 8p23.1 chromosome [26–28]. The region contains a cluster of defensin genes including the DEFB4 and the DEFB103 which encode human β-defensins 2 and 3 (hBD2, hBD3), respectively. Defensin genes encode small cationic peptides that have antimicrobial activity and have multi-functional activity: they function as chemo-
attractants for T-lymphocytes, monocytes and dendritic cells [29–32]. β-defensins induce the production of diverse chemokines and cytokines such as MCP-1, macrophage inflammatory protein 3-α (MIP-3), RANTES, IL-6, IL-10, interferon-inducible protein 10, TNF-α and IL-1β, mainly in keratinocytes [33,34]. hBD3 mediates monocyte/macrophage migration [35], can signal through melanocortin receptor 1 [36], and may function as an anti-inflammatory molecule [37].

The β-defensin cluster varies in copy number between 2 and 12 copies per diploid genome with most people having 2–7 copies [28,38–41]. Because, to date, all evidence suggests this defensin cluster varies in copy number en bloc, an assay for any point within the defensin cluster can be assumed to measure copy number across the whole region [42]. Though attention has moved from CNV discovery in small cohorts to CNV typing in larger cohorts, it is still a major challenge to determine exact copy numbers. Although several studies have been performed to characterize CNVs, comparing results from these studies has been hindered by small sample sizes and different study designs and analytical methods resulting in conflicting results [43,44] illustrating the need for an accurate method and controls for future work. In particular, the use of real-time QPCR methods, which appear attractive due

![Illustration of the PPRT assay](image)

**Figure 1. Illustration of the PPRT assay.** A. Primer design and sequence of region test and reference regions. The sequence shows several differences between chromosome 8 (test) and chromosome 21 (reference). The red arrow show the variable position used to distinguish test from reference amplicon sequences, and quantified by PPRT. F: forward primer, R: reverse primer, and S: sequencing primer. B. Pyrograms from PPRT testing of samples with 3 and 4 beta-defensin copies. Two variable sites are highlighted in yellow. The second variable site (corresponding to the site highlighted with the red arrow in Figure 1a), with the percentage of each allele shown, gave reproducible values and used for quantification. For the top pyrogram, the ratio of the C variant (representing the test amplicon) to the T variant (representing the reference amplicon) is 1.5:1, indicating a diploid copy number of three for the test sequence. For the bottom pyrogram, the ratio is 2:1, indicating a diploid copy number of four.

doi:10.1371/journal.pone.0016768.g001
to their universal applicability, high throughput and relative simplicity, has come under some scrutiny [45], with the suggestion that batch variation can generate false positive associations of copy number and disease [46,47]. Since CNVs may play a role in susceptibility to certain diseases, due to variation in gene expression [48,49], it is of great importance to find approaches to determine exact copy numbers.

PRT addresses one of the major drawbacks of QPCR, namely the problem of bias due to different amplification kinetics of test and reference amplicons [50]. By careful design of primers to a repeat region within the CNV, it is possible to amplify two almost identical regions using just one set of primer pair, the test amplicon within the CNV, and the reference amplicon outside the CNV, ideally on another chromosome. A small difference in length between the amplified products distinguishes test amplicon from reference amplicon. Using PCR and subsequent fragment analysis by capillary electrophoresis it is possible to determine the copy number. Here, we evaluate a simple, cost-effective, high-throughput adaptation of the PRT method to determine gene copy number using the pyrosequencing technique to quantify sequence differences between the test and reference PRT amplicons [42,51,52], and compare this pyrosequencing PRT (PPRT) with the published triplex PRT [53] method and real-time QPCR. We determined the gene copy numbers for 576 healthy individuals from five different populations, compared the copy number distributions generated by the different methods, and compared the copy number distributions across the different populations.

### Materials and Methods

#### Study population

Unrelated DNA samples from normal healthy individuals from five different demographic population groups, Denmark (n = 174), Czech Republic (n = 21), Ghana (n = 100), Portugal (n = 91), and the United Kingdom (the European Collection of Cell Cultures ECACC; Cat. No.: HRC-1 and HRC-2); (n = 190) were used in the study.

### Ethics statement

All samples were gathered with full ethical consent and appropriate documentation as stipulated by the ethical consent, which normally involved written informed consent. For Portuguese samples, the local ethics committee of Hospital Garcia de Orta, Almada, Portugal, gave its approval for a genetic study using blood samples from local patients and normal volunteers. For Czech samples, the study has been approved by the Ethical committee of the General Faculty Hospital in Prague. For Ghanaian samples, approval of the Institutional Review Board of Noguchi Memorial Institute for Medical Research, University of Ghana was given. For Danish samples, they are a standard set of anonymised DNA samples provided for standardisation purposes and quality assurance, and were not required under Danish law to pass the Danish Ethics Approval system. Other samples were from immortalised lymphoblastoid cell lines, which had been derived from B-cell lymphocytes with full ethical consent by the suppliers (ECACC and Coriell Cell Repositories).

#### DNA extraction

Genomic DNA was isolated from samples of venous blood, anticoagulated with EDTA and purified using the QiAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol and eluted in water. The UK samples were purified using an in-house magnetic bead affinity method.

### Table 1. Copy number estimates using different methods on a panel of DNA samples.

| Sample     | PRT (reference 50) | PPRT (this paper) | PRT (reference 42) | Triplex PRT (this paper) | MLPA (reference 42) | Q-PCR (this paper) |
|------------|-------------------|------------------|-------------------|------------------------|-------------------|-------------------|
| C0088      | 4                 | 4                | 3                 | 4                      | 4                 | 4                 |
| C0096      | 5                 | 5                | 3                 | 5                      | 5                 | 4                 |
| C0187      | 4                 | 4                | 4                 | 4                      | 4                 | 3                 |
| C0195      | 4                 | 4                | 4                 | 4                      | 4                 | 4                 |
| C0748      | 4                 | 3                | 4                 | 4                      | 4                 | 4                 |
| C0766      | 3                 | 2                | 2                 | 3                      | 3                 | 3                 |
| C0863      | 5                 | 5                | 4                 | 5                      | 5                 | 5                 |
| C0877      | 3                 | 3                | 3                 | 3                      | 3                 | 3                 |
| C0888      | 5                 | 5                | 4                 | 5                      | 5                 | 5                 |
| C0909      | 5                 | 4                | 4                 | 5                      | 5                 | 6                 |
| C0913      | 3                 | 3                | 3                 | 3                      | 3                 | 3                 |
| C0917      | 4                 | 4                | 3                 | 4                      | 4                 | 4                 |
| C0937      | 4                 | 4                | 4                 | 4                      | 4                 | 4                 |
| C0960      | 3                 | 3                | 2                 | 3                      | 3                 | 3                 |

This table summarises published data and data from this paper where a panel of DNA samples from the UK population have been typed for beta-defensin copy number by different laboratories using different methods.

doi:10.1371/journal.pone.0016768.t001

### Table 2. Percentage of discordant results between the three different methods.

|          | PPRT | Triplex PRT | QPCR |
|----------|------|-------------|------|
| PPRT     | -    | -           | -    |
| Triplex PRT | 47.3% | -           | -    |
| QPCR     | 67.7% | 60.2%       | -    |

Pairwise discordance rates are shown for a first-pass test of all 576 samples.

doi:10.1371/journal.pone.0016768.t002
Figure 2. Histograms of raw unrounded copy number estimates. The raw unrounded copy number estimates for all 576 samples analysed. Unrounded copy number estimates are in bins of 0.1, with the count of each bin displayed on the y-axis: a) from QPCR assay, b) from PPRT assay, and c) from triplex PRT assay. doi:10.1371/journal.pone.0016768.g002
and was obtained from ECACC (Porton Down, Salisbury, UK). Czech DNA samples were extracted using a routine “salting out” and ethanol precipitation procedure.

Quantitative real-time PCR for copy number determination

A duplex TaqMan real-time quantitative PCR-based assay was developed for the detection of beta-defensin genomic copy number using RNaseP as reference gene. Primers and probes for amplification of a region near the DEFB103 gene were designed using the Primer Express software, version 2.0 (Applied Biosystems, Foster City, CA). The sequences of the primers and probes were as follows: DEFB103 forward primer (5’ CAT AGG GAG CTC TGC CTT ACC A 3’); DEFB103 reverse primer (5’ TGC AGA ACA CAC CCA CTC ACT C 3’) and DEFB103 probe (5’ FAM - TGG GTT CCT AAT TAA C – MGB 3’). The sequence for RNaseP is not known since it is a commercial available kit (VIC labelled, Cat. no. 4316844, Applied Biosystems). The amplification efficiencies of the target genes and the reference genes were tested to be approximately equal not varying more than 5% from each other. Optimizing runs were performed to define limiting primer concentrations for the duplex assay. The PCR reactions (20 μl) were carried out in triplicate with 10–75 ng of template DNA, 1 x Brilliant II QPCR master mix (Stratagene, La Jolla, CA), 400 nM of DEFB103 probe, 600 nM DEFB103 primers and 1 x RNaseP primer mix. Each plate included triplicate wells of “no template control” and 4 control samples. QPCR was performed using a Stratagene MX3000P machine (Stratagene) using the following conditions 95°C for 10 min followed by 40 cycles of 95°C for 15 sec, and 60°C for 1 min. In all runs samples from Coriell Institute for Medical Research (Camden, NJ) with known copy number were included[50]: 3 copies per genome (Coriell cat no.: NA10861), 4 copies per genome (Coriell cat no.: NA07048), 5 copies per genome (Coriell cat no.: NA10846), and 7 copies per genome (Coriell cat no.: NA10847). These were used to generate a correction curve by linear regression, and corrected copy number estimates calculated for each sample calculated using this run-specific regression equation.

Paralogue Ratio Test for copy number determination

PRT was performed as described previously [53]. Briefly, the assay used comprises two PRT assays and a multiallelic ratio test [52] to gain three independent measurements of beta-defensin repeat copy number. This test, performed in duplicate, produces six estimates of beta-defensin copy number in a single fluorescent capillary run, and each test is independently normalised against six samples of known copy number to control for variation between experimental runs. The six values are combined using a maximum-likelihood method [53,54] to give the best estimate of the integer copy number for each sample, together with an associated significance value reflecting the confidence we have in that typed copy number compared to all other copy numbers between 1 and 10. For analyses involving raw non-integer copy number estimates, we calculated means of the six copy number estimates, each estimate weighted according to the inherent variability of each individual assay.
Pyrosequencing-based Parologue Ratio Test for Copy number determination

PRT was carried out essentially as described previously [50]. The beta-defensin cluster region on chromosome 8 and an identified parologue gene (HISP21 on chromosome 21) 3 kb distal to the DEFB4 gene with only two copies per genome were PCR amplified. The resulting PCR amplicons differed at 10 positions with an 8 bp (BLAST) difference in length. One of the positions where the amplicons differed was used to quantify the two chromosome regions against each other by pyrosequencing across it. Primers for the pyrosequencing assay were designed using the PSQ assay design software version 1.0.6 (Qiagen, Hilden, Germany). The following sequence was analysed with the position that varied between chromosome 8 and 21 marked with red: KATGCGYAT (Figure 1). For the PCR, 20 ng of genomic DNA in a total volume of 50 µl using a forward primer (5'-GAGGTCACTGTGATCAAAAAAGAT-3') and a reverse primer (5'-Biotin-AACCTTCACGACGC-TACTC-3') was used was used together with Q-solution (Qiagen), 10 mM dNTP and Tempase polymerase. PCR was performed on a thermocycler using the following conditions: 15 min at 95°C followed by 35 cycles of 95°C for 30 s, 53°C for 30 s and 72°C for 45 s and one extension step at 72°C for 10 min. The biotin-labeled PCR products were immobilized on streptavidin Sepharose (GE Healthcare, Uppsala, Sweden) by mixing 40 µl of the PCR product with 3 µl streptavidin Sepharose suspension, 40 µl water, and 37 µl 1 x binding buffer (Qiagen). The suspension was shaken at room temperature for 10 minutes. To remove unbiotinylated DNA the samples were sequentially washed in 70% ethanol for 5 seconds, 70% ethanol for 5 seconds, and 70% ethanol for 5 seconds, followed by washing in 80% ethanol for 5 seconds, and finally in water.

For each sample, 5 µl of the PCR product was used to test the QPCR assay, which was performed using the Pyro Gold Reagent Kit (Qiagen) in the PSQ 96 MA Pyrosequencer (Qiagen) according to the manufacturer’s instructions. The relative percentages of the two variants were calculated by the accompanying software and were used for the gene copy number determination. Positive controls with known copy number in each run were used to generate a correction curve by linear regression, and corrected copy number estimates calculated for each sample calculated using this run-specific regression equation. A “no template control” was included in each run.

Statistical analysis

Statistical analysis was performed using GraphPad InStat 3 (GraphPad Software, La Jolla, USA) and Microsoft Excel.

Results and Discussion

We have developed a version of the PRT method that uses pyrosequencing and quantification of different sequence variants to distinguish test and reference amplicons (pyrosequencing PRT, PPRT). A pyrosequencing approach to determining beta-defensin copy number has been described previously [42], using different primers and an alternative parologue on chromosome 5, giving results that differed considerably from MLPA and previously published estimates of the same samples [50]. Nevertheless, given the potential of PPRT to automated copy number typing, and the previously published examples of pyrosequencing to quantify alleles, a reliable PPRT method would be a very useful tool to investigate the role of beta-defensin copy number and disease. We designed an assay that would allow PCR amplification across a “test” region distal to DEFB4 co-amplifies a “reference” region on chromosome 21. Pyrosequencing of the product allows quantification of a particular sequence variant that reports copy number by distinguishing test from reference amplicons.

We determined beta-defensin gene copy number using PPRT and two other independent methods on DNA samples from 576 individuals from five populations. Comparison of copy number estimates for 14 samples measured using several different methods shows that triplex PRT and MLPA give exactly the same copy numbers as the previously published PRT method (Table 1). PPRT performs better than a previous pyrosequencing-based assay, but showed three discrepancies with PRT/triplex PRT/MLPA. Extending this analysis, we examined the correlation between QPCR and PPRT show no evidence of clustering (Figure 2a, 2b), which shows evidence of clustering, revealed by peaks in the histogram corresponding to integer copy numbers. This is due, at least in part, in repeat testing, because each triplex PRT copy number estimate is from duplicate testing of three different assays, compared to triplicate testing of one assay for the QPCR, and one test for the PRT. Indeed, on repeat testing of a selection of UK samples, the coefficient of variation for PPRT is 0.05 compared to 0.08 for triplex PRT, suggesting that PPRT is as precise as triplex PRT, although PPRT assays a single locus, while the triplex PRT assays three different loci within the beta-defensin CNV.

Both PPRT and triplex PRT give a copy number distribution of between 2 and 6 copies, with a few samples showing a higher copy number. However, the QPCR assay gives a considerably broader distribution, with more samples showing apparently higher copy number, and a significant number of samples showing copy number higher than 10. This is reflected in the Bland-Altman plots comparing the raw copy number estimates between the different methods (Figure 3), and the observation that QPCR can overestimate copy number values agrees with other reported studies [55].

We took the raw copy number data and divided, according to cohort, by separating the Ghanaian and Portuguese cohorts from the UK, Danish and Czech cohorts. Plotting this raw data as a histogram shows that DNA cohort origin is clearly responsible for systematic copy number calling bias in QPCR between “poor
quality” DNA from the Portuguese and Ghanaian cohorts and “good quality” DNA from the UK, Danish and Czech cohorts (Figure 4a) but had no effect on copy number calling for the two PRT-based methods (Figure 4b and 4c). For the UK, Danish and Czech cohorts, QPCR gives a copy number distribution in a range comparable with the PRT-based methods, while for the Ghanaian and Portuguese cohorts QPCR systematically overestimates copy number, often by several copies. Because each cohort was analysed as a batch, it is possible that biases in the normalisation to known copy number controls included on every PCR plate (see Methods) could generate this effect. We compared the results from the known copy number controls across each cohort-specific plate for all three methods, and found no evidence of systematic differences (Figure 5).

We therefore reasoned that systematic difference in DNA quality between the DNA sample cohorts may be responsible for this effect. Cukier and colleagues recently showed that degraded DNA could give spurious CNV findings despite the presence of multiplexed internal samples in QPCR assays [45]. Although these five cohorts are from different biological sources, DNA extracted using different methods, and have different histories of transport and storage associated with them, they do not appear to vary with DNA “quality” (Table 3). We investigated whether the systematic bias in QPCR results was due to DNA degradation by analysing selected samples by agarose gel electrophoresis or whether it was due to salt contamination by examining absorbance at 230 nm. Neither measure correlated with the “quality” of the DNA in giving appropriate QPCR results, so we do not yet understand the physical basis for the different DNA qualities of these cohorts.

This raises questions about the applicability of QPCR in measuring DNA copy number, particularly as we cannot, as yet, identify the factor that is responsible for this effect, ruling out a priori determination of the applicability of each sample for copy number calling by QPCR. Furthermore, it is unclear whether internal controls constructs would remove this effect, given that it is a property of the genomic DNA itself rather than any effect of aberrant normalisation.

Taking the triple PRT data as representing the correct copy number of the samples typed, we investigated whether there was any significant difference between copy number distributions in the five different populations. There was no significant difference between the means (one-way ANOVA, p > 0.05), reflecting essentially no difference between populations within Europe or between European and Ghanaian populations (Table 4). This is consistent with previous studies [39]. This probably reflects the high mutation rate at this locus, causing any population specific signatures to be rapidly erased. This also means that real case-control differences from robust studies are less likely to be confounded by cryptic population stratification than similar SNP studies, although we would recommend that population stratification is controlled for as far as possible.

Differences in beta-defensin copy number may have important clinical consequences in the susceptibility to, and progression of, a variety of diseases with an inflammatory or infectious etiology.
Accurate and precise methods for measuring copy number are essential when investigating subtle changes in copy number distribution between patients and healthy controls, which may reflect an effect of beta-defensin copy number on susceptibility to the disease under study. In summary, we show that PPRT is a practical high-throughput approach, although we would recommend multiplicate PPRTs per sample are required for sufficient accuracy for case-control analyses, and careful quality-control performed for every experiment. PPRT is cost-effective, with a single test priced around $0.75, compared with around $1.2 for a tripplex PRT. We hope that with an increasing focus on reliable methods to type beta-defensin copy number variation we will be in a position to investigate the role of this complex locus in disease.

Acknowledgments

We would like to thank John Armour (University of Nottingham, UK) for providing us with copy number control samples and Britta Hansen and Ida Haugeard Bøtcher for expert technical assistance.

Author Contributions

Conceived and designed the experiments: PF PSA. Performed the experiments: PF CJ RJH HB. Analyzed the data: PF CJ RJH EJH. Contributed reagents/materials/analysis tools: MT DD ML LV AV JF. Wrote the paper: PF EJH.

References

1. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, et al. (2006) Global variation in copy number in the human genome. Nature 444: 444–454.
2. Carter NP (2007) Methods and strategies for analyzing copy number variation using DNA microarrays. Nat Genet 39: S16–S21.
3. Pinto D, Marshall C, Feuk L, Scherer SW (2007) Copy-number variation in control population cohorts. Hum Mol Genet 16 Spec No. 2: R168-R173.
4. Conrad DF, Pinto D, Redon R, Feuk L, Gokcumen O, et al. (2010) Origins and functional impact of copy number variation in the human genome. Nature 464: 704–712.
5. Kidd JM, Cooper GM, Donahue WF, Hayden HS, Sampas N, et al. (2008) Mapping and sequencing of structural variation from eight human genomes. Nat Genet 39: S16–S21.
6. Korbel JO, Urban AE, Allofort JP, Godwin B, Grubert F, et al. (2007) Paired-end mapping reveals extensive structural variation in the human genome. Science 318: 420–426.
7. Sebat J, Lakshmi B, Troge J, Alexander J, Young J, et al. (2004) Large-scale copy number polymorphism in the human genome. Science 305: 525–528.
8. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, et al. (2004) Detection of large-scale variation in the human genome. Nat Genet 36: 949–951.
9. Abshuler D, Daly MJ, Lander ES (2008) Genetic mapping in human disease. Science 322: 881–888.
10. Hollox EJ, Huffmier U, Zeeuwen PL, Palla R, Lascorz J, et al. (2008) Psoriasis is associated with increased beta-defensin genomic copy number. Nat Genet 40: 23–25.
11. de Cid R, Riveira-Munoz E, Zeeuwen PL, Robarge J, Liao W, et al. (2009) Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet 41: 211–215.
12. Huffmier U, Berghofer JGM, Becker T, Armour JA, Traupe H, et al. (2010) Replication of LCE3C-LCE3B CNV as a Risk Factor for Psoriasis and Analysis of Interaction with Other Genetic Risk Factors. J Invest Dermatol 130: 979–984.
13. Abrahams BS, Geschwind DH (2008) Advances in autism genetics: on the threshold of a new neurobiology. Nat Rev Genet 9: 341–355.
14. Huw K, Taudien S, Groth M, Rosenstiel P, Szatmari K, et al. (2008) Genetic variants of the copy number polymorphic beta-defensin locus are associated with sporadic prostate cancer. Tumour Biol 29: 83–92.
15. Stenfors H, Rujescu D, Cichon S, Perélhainen OP, Ingason A, et al. (2008) Large recurrent microdeletions associated with schizophrenia. Nature 455: 232–236.
beta-defensin 3 has immunosuppressive activity in vitro and in vivo. Eur J Immunol 40: 1073–1078.

30. Hollox EJ, Davies J, Griessenbach U, Burgess J, Alton EW, et al. (2005) Beta-defensin genomic copy number is not a modifier locus for cystic fibrosis. J Negat Results Biomed 4: 9.

31. Heinzen EL, Need AC, Hayden KM, Chiba-Falek O, Roses AD, et al. (2010) Genome-wide scan of copy number variation in late-onset Alzheimer’s disease. J Alzheimers Dis 19: 69–77.

32. Waterman MA, van Ruisen F, de Wiesel M, Bordaewijk L, Samijn JP, et al. (2010) Copy number variation upstream of PM22 in Chorot-Marie-Tooth disease. Eur J Hum Genet 18: 412–418.

33. Zhang B, Serman P, Liu P, Gonçaga-Jauregui C, Towne CF, et al. (2010) Mechanisms for Nonrecurrent Genetic Rearrangements Associated with CMT1A or HNPP: Rare CNVs as a Cause for Missing Heritability. The American Journal of Human Genetics 86: 892–903.

34. Thomas B, Real MF (2007) Parkinson’s disease. Human Molecular Genetics 16: R183–R194.

35. Schardl H, Aiman TJ, Vye TJ (2009) Copy number variation in the human genome and its implication in autoimmunity. Clin Exp Immunol 156: 12–16.

36. Aldred PM, Hollox EJ, Armour JA (2005) Copy number polymorphism and expression level variation of the human alpha-defensin genes DEFA1 and DEFA3. Hum Mol Genet 14: 2045–2052.

37. Linzmeyer R, Ho CH, Hoang BV, Ganz T (1999) A 450-kb contig of defensin genes on human chromosome lp32. Gene 233: 205–211.

38. Hollox EJ, Armour JA, Barber JC (2003) Extensive normal copy number variation of a beta-defensin antimicrobial-gene cluster. Am J Hum Genet 73: 591–600.

39. Ganz T (2003) Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 3: 710–720.

40. Ronaghi M, Karamohamed S, Pettersson B, Uhlén M, Nyren P (1996) Real-time DNA sequencing using detection of pyrophosphate release. Anal Biochem 242: 84–89.

41. Hollox EJ, Barber JC, Brookes AJ, Barber JC (2008) Defensins and the dynamic genome: What we can learn from structural variation at human chromosome band 8p23.1. Genome Res 18: 1686–1697.

42. Groth M, Szafiranski K, Taudien S, Huse K, Mueller O, et al. (2008) High-resolution mapping of the lp23.1 beta-defensin cluster reveals strictly concordant copy number variation of all genes. Hum Mutat 29: 1247–1254.

43. Bentley RW, Pearson J, Geary RB, Barclay ML, McKinney C, et al. (2009) Association of Higher DEFB4 Genomic Copy Number With Crohn’s Disease. Am J Gastroenterol 104: 334–339.

44. Fellermann K, Stange DE, Schaafelder E, Schmizl H, Wehkamp J, et al. (2006) A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet 79: 439–448.

45. Cukier HN, Pericak-Vance MA, Gilbert JR, Hedges DJ (2009) Sample degradation leads to false-positive copy number variation calls in multiplex real-time polymerase chain reaction assays. Anal Biochem 386: 218–290.

46. Field SF, Howson JM, Maier LM, Walker S, Walker NM, et al. (2009) Experimental aspects of copy number variant assays at GCC3L1. Nat Med 15: 1115–1117.

47. Hollox EJ (2010) Beta-defensins and Crohn’s disease: confusion from counting copies. Am J Gastroenterol 105: 380–382.

48. Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, et al. (2007) Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 315: 448–453.

49. Groth M, Wiegand C, Szafiranski K, Huse K, Kramer M, et al. (2010) Both copy number and sequence variations affect expression of human DEFB4. Genes Immun 11: 438–446.

50. Armour JA, Palla R, Zeeuwen PL, den Heijer M, Schalkwijk J, et al. (2007) Concordant copy number variation of all genes. Hum Mutat 29: 1247–1254.

51. Bakar SA, Hollox EJ, Armstrong J, Hadcock J, Crook D, et al. (2009) Allelic recombination between distinct alpha- and beta-defensin regions at 8p23.1. Nucleic Acids Res 35: e19.

52. Semple F, Webb S, Li HN, Patel HB, Perretti M, et al. (2010) Human beta-defensin 3 has immunosuppressive activity in vitro and in vivo. Eur J Immunol 40: 1073–1078.

53. Ronaghi M, Karazamohamed S, Pettersson B, Uhlén M, Nyren P (1996) Real-time DNA sequencing using detection of pyrophosphate release. Anal Biochem 242: 84–89.

54. Fellermann K, Stange DE, Schaafelder E, Schmizl H, Wehkamp J, et al. (2006) A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet 79: 439–448.

55. Cukier HN, Pericak-Vance MA, Gilbert JR, Hedges DJ (2009) Sample degradation leads to false-positive copy number variation calls in multiplex real-time polymerase chain reaction assays. Anal Biochem 386: 218–290.

56. Field SF, Howson JM, Maier LM, Walker S, Walker NM, et al. (2009) Experimental aspects of copy number variant assays at GCC3L1. Nat Med 15: 1115–1117.

57. Hollox EJ (2010) Beta-defensins and Crohn’s disease: confusion from counting copies. Am J Gastroenterol 105: 380–382.

58. Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, et al. (2007) Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 315: 448–453.

59. Groth M, Wiegand C, Szafiranski K, Huse K, Kramer M, et al. (2010) Both copy number and sequence variations affect expression of human DEFB4. Genes Immun 11: 438–446.